Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials

BACKGROUND: Progression-free survival (PFS) exhibits suboptimal performance as the surrogate endpoint for overall survival (OS) in trials studying immune checkpoint inhibitors (ICIs). Here we propose a novel surrogate endpoint, modified PFS (mPFS), which omits the events of disease progression (but...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother Cancer
Main Authors: Wang, Zi-Xian, Wu, Hao-Xiang, Xie, Li, Lin, Wu-Hao, Liang, Fei, Li, Jin, Yang, Zhi-Min, Xu, Rui-Hua
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2021
Teme:
Clinical/Translational Cancer Immunotherapy
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8021890/
https://ncbi.nlm.nih.gov/pubmed/33795385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002114
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki